NUWENuwellis, Inc.

Nasdaq nuwellis.com


$ 0.17 $ -0.01 (-5 %)    

Monday, 06-May-2024 15:57:23 EDT
QQQ $ 439.97 $ 4.77 (1.1 %)
DIA $ 388.40 $ 1.68 (0.43 %)
SPY $ 516.34 $ 5.28 (1.03 %)
TLT $ 90.16 $ 0.35 (0.39 %)
GLD $ 215.21 $ 2.24 (1.05 %)
$ 0.171
$ 0.18
$ 0.00 x 0
$ 0.00 x 0
$ 0.16 - $ 0.18
$ 0.13 - $ 4.59
3,493,028
na
335,913
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-11-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-03-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-03-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-25-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-05-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-05-2020 12-31-2019 10-K
18 11-08-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 02-21-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-22-2018 12-31-2017 10-K
26 11-02-2017 09-30-2017 10-Q
27 08-10-2017 06-30-2017 10-Q
28 05-12-2017 03-31-2017 10-Q
29 03-08-2017 12-31-2016 10-K
30 11-14-2016 09-30-2016 10-Q
31 08-11-2016 06-30-2016 10-Q
32 05-05-2016 03-31-2016 10-Q
33 03-15-2016 12-31-2015 10-K
34 11-05-2015 09-30-2015 10-Q
35 08-05-2015 06-30-2015 10-Q
36 05-07-2015 03-31-2015 10-Q
37 03-20-2015 12-31-2014 10-K
38 10-31-2014 09-30-2014 10-Q
39 08-12-2014 06-30-2014 10-Q
40 05-13-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nuwellis-receives-uspto-notice-of-patent-allowance-for-innovative-pediatric-crrt-technology

Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid...

 nuwellis-announces-pricing-of-27m-public-offering-of-1125m-shares-of-common-stock-and-warrants-to-purchase-up-to-an-aggregate-of-16875m-shares-of-its-stock-at-a-combined-public-offering-price-024share

Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a medical technology company focused on transformin...

 nuwellis-has-received-a-notice-of-allowance-for-its-us-patent-application-18463612-titled-venous-blood-flow-stimulator-for-extracorporeal-therapy

https://patentcenter.uspto.gov/applications/18463612/ifw/docs 

 nuwellis-filed-us-patent-application-20240108533---venous-blood-flow-stimulator-for-extracorporeal-therapy

https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240108533

 nuwellis-announced-results-from-two-new-clinical-data-analyses-from-the-avoid-hf-trial-demonstrating-benefits-of-aquadex-system-for-heart-failure

- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failur...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION